First World Congress on Therapies against Obesity:
Perspectives for Pharmaceutical and Natural Products
Paris Anti-Obesity Therapies 2006
Institut Pasteur - Paris - France
May 18-19, 2006
Thursday May 18 2006
8:30 Registration and Welcome Address
Dr Marvin Edeas, President of the French Society of Antioxidants, Paris, France
9:00 Economic Impact of Anti-Obesity Drugs
What market share do anti-obesity drugs have in France, in Europe and world wide?
What are the latest trends in the anti-obesity drug market?
Mrs Katia Musitu, IMS Health, London, UK
SESSION 1: General Presentation on Obesity
Chairmen: Pr Vojtech Hainer and Dr Sander Houten
9:30 Obesity should be accepted as a disease
Definition – Prevalence - Pathogenesis

Classification of obesity (degree, body fat distribution) – cut-off points

Epidemiological data

Pathogenesis
o
Regulation of energy balance (genetic and neurohormonal factors: orexigenic and anorexigenic
pathways)
o
Role of genetic factors (rare: monogenic and syndromic forms of obesity vs. common polygenic
obesities)
o
Role of environmental factors: positive energy balance as a result of the high energy density diet and
low physical activity and adoption of a sedentary lifestyle
o
Nutrients in body weight regulation
o
Gene – environment interaction and body weight change
Obesity Associated Diseases

Metabolic syndrome – definition, crucial role of abdominal obesity

Diseases:
o
Metabolic : type 2 diabetes mellitus, hyper/dyslipidaemia, hyperuricaemia, inflammatory response
o
Cardiovascular: hypertension, coronary heart disease, stroke, endothelial dysfunction, thrombosis
o
Other: cancer, sleep apnoea, depression, infertility, osteoarthritits etc.
Pr Vojtech Hainer, Obesity Management Center, Endocrine Institute, Prague, Czech Republic.
10:00 – Break and Poster Session
10:30 Obesity in Animals: an overview
What are the animals concerned by obesity?
What are the differences or similarities with obesity in humans?
What are the different ways to manage this problem?
Dr Christophe Blanckaert, Veterinary Clinic Les Margats, Boulogne sur Mer, France
11:00 Role of Circadian Clock in the Management of Obesity
What is the role of the clock gene in the circadian rhythmicity?
What are the relationships between the circadian clock and the fuel metabolism of the organism?
What are the impacts of circadian clock dysfunction on weight management?
Dr Fred Turek, Northwestern University, Evanston, Illinois, USA.
11:30 Oral Communication Session 1: What are the New Scientific Insights in the Obesity Field?
The impact of overweight/obesity and associated cardiometabolic risk factor clusters on health-related quality of life in a
nationally representative sample of adults in the United States
Dr Patrick Sullivan, University of Colorado, Denver, Colorado, USA
Proinflammatory cytokine polymorphisms and the risk of obesity
Dr Fabio Pereira, University of Porto, Porto, Portugal
Omental adipose tissue ZFP36 mRNA abundance is correlated with fasting insulin, insulin resistance (HOMA-ir) index
and plasma adiponectin levels in women
Dr Luigi Bouchard, Laval University, Quebec, Quebec, Canada
12:00 Poster Session
12:30 Lunch
SESSION 2: What are the Strategies Used to Prevent and/or Treat
Obesity?
Chairmen: Dr Christian Broberger and Pr Olivier Ziegler
14:00 Current Pharmacotherapies and New Drugs in Development
Appetite suppressors: example of Sibutramine. Mechanism of action, efficiency and side effects.
Metabolism modificators: example of Orlistat. Mechanism of action, efficiency and side effects.
New drugs in development: Axokine, Rimonabant and Bupropion SR.
Pr Olivier Ziegler,Hospital of Nancy, Toul, France
14:30 Brain Regulation of Energy Metabolism
Which parts of the central nervous system control hunger and energy expenditure?
How do these regions stay informed about the metabolic state of the body?
Which transmitters and, in particular, neuropeptides are involved?
Dr Christian Broberger, Department of neurosciences, Karolinska Institutet, Stockholm, Sweden.
15:00 Targeting the Lipid and Carbohydrate Metabolism
Inhibition of fatty acids absorption
Inhibition of adipogenesis and fat storage
Stimulation of enzymes involved in lipolysis
Dr Yuguang Shi, Hershey Medical Center, Penn State University, Hershey, Pennsylvania,USA
15:30 Bariatric Surgery
What are the different kinds of bariatric surgeries? Gastroplasty, gastric bypass, biliopancreatic diversion, gastric
banding
What efficiency for what risk? Clinical data
Dr Jérôme Dargent, Policlinic of Rillieux, Rillieux-le-pape, France
16:00 Break and Poster Session
SESSION 3: Impact of Nutrition and/or Nutraceutical in Obesity
Prevention and Treatment
Chairmen: Dr Yuguang Shi and Dr Fred Turek
16:30 Dietary Calcium Intake, Dairy Products and Obesity: Overview and Perspectives
What are the effects of calcium on body weight?
What are its mechanisms of action?
What is the impact of dairy product consumption on body weight?
What is more effective: calcium in dairy products or in food supplements?
Dr Michael Zemel, FACN, University of Tennessee, Knoxville, Tennessee, USA
17:00 Beneficial effects of bile acids: a new way to treat obesity by food supplementation?
What are the physiological effects of cholic acid? (lowering of triglyceride levels, increasing energy expenditure)
Which are the mechanisms involved to product these effects?
Could food supplementation by cholic acid be an interesting way to treat obesity?
Dr Sander Houten, Laboratory Genetic Metabolic Diseases, University of Amsterdam, Amsterdam, The
Netherlands
17:30 - Round Table Discussion with the Participation of Multinational Food Companies
What are the policies, strategies and initiatives of big food industries to fight against obesity?
What is the future of nutritional or natural ingredient supplemented food in the prevention of obesity?
What is the efficiency of these new products?
Which are the current and future products on the obesity market?
In presence of Pr Guy-Grand, Hôtel Dieu, paris, France and the Scientific Committee
20:30 Gala Dinner
Friday May 19 2006
SESSION 4: New Targets for Therapies Against Obesity
Chairmen: Pr Bart Staels and Dr Cathy Chan
9:00 Interesting Molecular Targets: the Peroxisome Proliferator-Activated Receptors (PPARs)
What is the connection between glucids and lipid metabolism
The different isoforms and their respective role in lipid and glucose homeostasis
Future directions for new therapies against obesity: example of PPAR-δ agonists
Pr Bart Staels, University of Lille 2, Lille, France
9:30 An RNAi-based Approach to Metabolic Disease
What is RNAi technology?
What are the different in vitro and in vivo steps to indentify a potential target?
What are the new targets identified by RNAi technology for obesity?
Pr Michael Czech, University of Massachusets, Worcester, USA
10:00 Break and Poster Session
10:30 Inflammation and Obesity: a New Field for Therapy?
What is the link between inflammation and obesity?
Inflammatory cytokines and oxidative stress: what role for antioxidant molecules?
What are the emerging pathways for the development of new therapies against obesity?
Dr Alain Géloën, University of Lyon 1, Lyon, France
11:00 Role of Mitochondria and Uncoupling Proteins in Obesity and Insulin Secretion
Mitochondria and thermogenesis
Uncoupling proteins and insulin secretion
Uncouplig proteins: a new target to treat obesity?
Dr Cathy Chan, Department of Biomedical Sciences, University of Prince Edward Island, Charlottetown, Prince
Edward, Canada.
11:30 Oral Communication Session 2: What are the Potential New Targets and Useful Pathways for New
Therapies Against Obesity?
Transgenic rabbits overexpressing human APOb mRNA editing gene (APOBEC-1) are obese
Itzik Harosh, ObeTherapy, Evry, France
INOS gene disruption potentiates the anti-diabetic effects of rosiglitazone in obese mice: role of the adiponectin-ampk
pathway
Patrice Dallaire, Laval University, Quebec, Quebec, Canada
Activation of nuclear hormone receptors by Guggulipids and its component commipheric acid
Claire Cornick, University of Buckingham, UK
Increased adiposity and relative body fat mass is accompanied by mitochondrial abnormalities in an ovine model of
intrauterine nutrient restriction
Piran Shelley, St Thomas’ Hospital KCL, London, United Kingdom.
12:10 Poster Session
12:30 Lunch
SESSION 5: Latest Advances on Natural Ingredients and Alternative
Therapeutics against Obesity
Chairmen: Pr Edzard Ernst and Dr Bernard Schmitt
14:00 Conjugated Linoleic Acid (CLA): Overview and Latest Advances
Does CLA induce diabetes?
Dr Bernard Schmitt, CERN/CHBS, Lorient, France
14:30 Potential Use of Natural Antioxidants in the Treatment of Obesity
Inhibition of the oxidative stress vicious circle
How can antioxidants control mitochondria metabolism?
Which antioxidant can we use to treat obesity: green tea extract, lipoic acid, riboflavin and L-Carnitine
Dr Marvin Edeas, President of the French Society of Antioxidants, Paris, France
15:00 Dietary Supplements and Body-Weight Reduction
What are the results of a systematic review of the literature about dietary supplements?
What is the impact of dietary supplements on body-weight reduction?
Pr Edzard Ernst, University of Exeter and Plymouth, Exeter, UK
15:30 Natural Appetite Suppressants: Reducing caloric intake in the natural way.
Overview of the regulatory mechanisms that controls appetite.
Latest innovations with a special focus on natural ingredients acting on gut hormones.
Efficiency and mechanism of action of an original ingredient derived from pine nuts
Dr Sandra Einerhand, Lipid Nutrition, Wormerveer, The Netherlands
16:00 Break and Poster Session
16:30 Point of View of a Medical Doctor: Which Natural ingredients could be efficient treatments of Obesity in
medical everyday practice?
Green coffee beans, Ephedra, Fenugreek, Garcinia cambodgia, Guarana, Ispaghula, Konjac, Manganese, Nopal, Apple
pectin, Phaseolus vulgaris, Phlorizin, Hieracium pilosella, calcium, potassium, chitosan.
Dr Paul Goetz, Strasbourg, France
17:00 Communication Session 3: What are the Latest Innovations in the Natural ingredients and Natural
Products Field to Fight or Prevent Obesity?
Increased Adiponectin but not SCD1 Activity Correlates with Reduced Body Weight Gain in CLA and PUFA Fed Zucker
Fatty Rats.
Leslie Ratkay, Xenon Pharmaceuticals Inc, Burnaby, Canada
Effect of caralluma fimbriata extract on appetite and weight control
Ramasamy Venkatesh, St. John’s National Academy of Health Sciences, Bangalore, India
Molecular mechanism of appetite suppression by a novel calcium/potassium salt of (–)-hydroxycitric acid (HCA-SX)
Debasis Bagchi, Creighton University Medical Center, Omaha, USA
17:30 Discussion and Conclusion: What are the Perspectives for Anti-Obesity Therapies? What Criteria Should
have the Ideal Molecule and the Ideal Strategy to Treat and/or Prevent Obesity?
In presence of the Scientific Committee
Anti-Obesity Therapies 2006 Innovation Award
The scientific committee will name the most innovative project upon oral or poster presentation